

Res. Asst. Mustafa Murat ÖZBALAK

Personal Information

Email: mozbalak@istanbul.edu.tr

Web: <http://aves.istanbul.edu.tr/4931/>

Address: Kartaltepe Mah. Necmeddin Sadak Sok. No:6 Tan Apt. Kat:4 Daire:12 Bakırköy/İSTANBUL

International Researcher IDs

ORCID: 0000-0002-3040-4052

Yoksis Researcher ID: 176894

Biography

Murat Ozbalak, M.D., was born in 1984 in Istanbul. Following his primary education in F.M.V. Ozel Işık Primary School, he finished highschool in Galatasaray Highschool. He was graduated from Istanbul University Cerrahpasa Medica Faculty English Program in 2009. He completed his residency in Istanbul University Cerrahpasa Medical Faculty in 2015. He worked in Batman Kozluk State Hospital between November 2015 and April 2017 and then, in Istanbul Bahcelievler State Hospital until February 2018. He is Hematology fellow in Istanbul Medical Faculty since June 2018. He is a PhD candidate in the Immunology Department of Aziz Sancar Experimental Medicine Institute.

Education Information

Doctorate, Istanbul University, Aziz Sancar Institute Of Experimental Medicine, Department of Immunology, Turkey 2018 - Continues

Post Doctorate of Medicine, Istanbul University, Istanbul Medical Faculty, Division Of Medical Sciences , Turkey 2018 - 2021

Expertise In Medicine, İstanbul University-Cerrahpaşa, Cerrahpasa Faculty Of Medicine, Department Of Internal Medicine, Turkey 2010 - 2015

Undergraduate, İstanbul University-Cerrahpaşa, Cerrahpasa Faculty Of Medicine, English Education Program, Turkey 2003 - 2009

Foreign Languages

English, C1 Advanced

French, C1 Advanced

Italian, A1 Beginner

Dissertations

Expertise In Medicine, Killer Immunoglobuline Like Receptor gene analysis in Chronic Lymphocytic Leukemia and its relation with autoimmunity, İstanbul University-Cerrahpaşa, Cerrahpasa Faculty Of Medicine, Department Of Internal Medicine, 2015

Research Areas

Medicine, Health Sciences, Internal Medicine Sciences, Internal Diseases , Hematology, Immunology and Rheumatology

Academic Titles / Tasks

Specialization Student, Istanbul University, Istanbul Medical Faculty, Division of Medical Sciences , 2018 - 2021

Specialization Student, İstanbul University-Cerrahpaşa, Cerrahpasa Faculty Of Medicine, Department Of Internal Medicine, 2010 - 2015

Published journal articles indexed by SCI, SSCI, and AHCI

- I. **Overview of clinical and genetic features of CML patients with variant Philadelphia translocations involving chromosome 7: A case series**
Bayrak A. G. , Daglar Aday A, Yavuz A. S. , Nalcaci M., Ozbalak M. M. , Cefle K., Ozturk Ş., Palanduz S.
LEUKEMIA RESEARCH, vol.111, 2021 (SCI-Expanded)
- II. **Brentuximab vedotin consolidation therapy after autologous stem-cell transplantation in patients with high-risk Hodgkin lymphoma: Multicenter retrospective study.**
Akay O. M. , Ozbalak M. M. , Pehlivan M., Yildiz B., Uzay A., Yigenoglu T. N. , Elverdi T., Kaynar L., Ayyildiz O., Yonal Hindilerden I., et al.
Hematological oncology, vol.39, no.4, pp.498-505, 2021 (SCI-Expanded)
- III. **Raman tweezers as an alternative diagnostic tool for paroxysmal nocturnal hemoglobinuria.**
Soysal K. B. , Parlatan S., Mastanzade M., Ozbalak M. M. , Yenerel M. N. , ÜNLÜ M. B. , Başar G., Parlatan U.
Analytical methods : advancing methods and applications, vol.13, no.35, pp.3963-3969, 2021 (SCI-Expanded)
- IV. **Brentuximab Vedotin Consolidation Therapy after Autologous Stem-Cell Transplantation in Patients with High-Risk Hodgkin Lymphoma: Multi-Center Retrospective Study**
Ozbalak M. M. , Akay O. M. , PEHLİVAN M., Yildiz B., UZAY A., Yigenoglu T. N. , ELVERDİ T., KAYNAR L., Ayyildiz O., Hindilerden I. Y. , et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, vol.21, 2021 (SCI-Expanded)
- V. **Nivolumab for relapsed or refractory Hodgkin lymphoma: real-life experience**
Bekoz H., ÖZBALAK M. M. , Karadurmus N., PAYDAŞ S., Turker A., TOPTAŞ T., Tuglular T. F. , Altuntas F., Cakar M. K. , SÖNMEZ M., et al.
ANNALS OF HEMATOLOGY, vol.99, no.11, pp.2565-2576, 2020 (SCI-Expanded)
- VI. **Long-term results of brentuximab vedotin in relapsed and refractory Hodgkin lymphoma: multi-center real-life experience.**
Ozbalak M. M. , SALİHOĞLU A., Soysal T., Karadogan I., PAYDAŞ S., Ozdemir E., Yildiz B., Karadurmus N., KAYNAR L., Yagci M., et al.
Annals of hematology, vol.99, no.2, pp.301-307, 2020 (SCI-Expanded)
- VII. **Venetoclax-Rituximab in Chronic Lymphocytic Leukemia**
Ferhanoglu B., Ozturk E., ÖZBALAK M. M.
NEW ENGLAND JOURNAL OF MEDICINE, vol.378, no.22, pp.2141-2143, 2018 (SCI-Expanded)
- VIII. **Nivolumab for relapsed or refractory Hodgkin lymphoma: real-life experience.**
Bekoz H., Karadurmus N., Paydas S., Turker A., Toptas T., Tuglular T. F. , Sonmez M., Gulbas Z., Tekgunduz E., Kaya A. H. , et al.
Annals of oncology : official journal of the European Society for Medical Oncology, vol.28, no.10, pp.2496-2502, 2017 (SCI-Expanded)
- IX. **Use of fluorodeoxyglucose positron emission tomography for diagnosis of bleomycin-induced pneumonitis in Hodgkin lymphoma**
Falay O., Ozturk E., Bolukbasi Y., Gumus T., Ornek S., ÖZBALAK M. M. , Cetiner M., Demirkol O., Ferhanoglu B.

LEUKEMIA & LYMPHOMA, vol.58, no.5, pp.1114-1122, 2017 (Journal Indexed in SCI)

- X. **Comparison of International Prognostic Index and NCCN-IPI in 324 patients with de novo diffuse large B-cell lymphoma: a multi-center retrospective analysis.**
ÖZTÜRK E., ÖZBALAK M. M. , Berk S., Erdoğan I., AVŞAR E., DOLGUN A., ÇETİNER M., MANDEL N. K. , YALNIZ F. F. , ELVERDİ T., et al.
Leukemia & lymphoma, vol.57, pp.1211-4, 2016 (SCI-Expanded)
- XI. **Is valganciclovir really effective in primary effusion lymphoma: case report of an HIV(-) EBV(-) HHV8(+) patient.**
Ozbalak M. M. , TOKATLI I., Ozdemirli M., Tecimer T., Ar M. C. , ORNEK S., KORUGLU A., LALELI Y., FERHANOGLU B.
European journal of haematology, vol.91, no.5, pp.467-9, 2013 (Journal Indexed in SCI Expanded)
- XII. **An unusual presentation of a chronic lymphocytic leukemia patient with 17p deletion after reduced-intensity transplantation: Richter syndrome and concomitant graft-versus-host disease--case report.**
Salihoglu A., Ozbalak M. M. , Keskin D., Tecimer T., Soysal T., Ferhanoglu B.
Transplantation proceedings, vol.45, no.7, pp.2845-8, 2013 (Journal Indexed in SCI Expanded)
- XIII. **Azacitidine has limited activity in 'real life' patients with MDS and AML: a single centre experience.**
Ozbalak M. M. , Cetiner M., Bekoz H., Atesoglu E. B. , Ar C., Salihoglu A., Tuzuner N., Ferhanoglu B.
Hematological oncology, vol.30, no.2, pp.76-81, 2012 (Journal Indexed in SCI Expanded)
- XIV. **Severe bone marrow failure due to valganciclovir overdose after renal transplantation from cadaveric donors: four consecutive cases.**
Ar M. C. , Ozbalak M. M. , Tuzuner N., Bekoz H., Ozer O., Ugurlu K., Tabak F., Ferhanoglu B.
Transplantation proceedings, vol.41, no.5, pp.1648-53, 2009 (Journal Indexed in SCI Expanded)
- XV. **Prognostic significance of micro vessel density in diffuse large B cell lymphomas**
Soer M., Ozbalak M. M. , Senocak M., Soysal T., Ferhanoglu B., Molinas N., Tuzuner N.
VIRCHOWS ARCHIV, vol.451, no.2, pp.357-358, 2007 (Journal Indexed in SCI)
- XVI. **Primary cutaneous T-cell lymphomas other than mycosis fungoides and primary cutaneous CD30(+) lymphoproliferative disorders**
Ozbalak M. M. , Demirkesen C., Oguz O., Onsun N., Tuzuner N.
VIRCHOWS ARCHIV, vol.451, no.2, pp.456, 2007 (Journal Indexed in SCI)

Articles Published in Other Journals

- I. **Salvage Intrapartum Splenectomy for the Treatment of Transfusion-refractory Anaemia in a β -thalassemia Intermedia Patient**
Saraç Sivriköz T., Özbalak M. M. , Tükenmez M., Beşişik S.
Journal of College of Physicians and Surgeons Pakistan, vol.32, no.10, pp.1344-1346, 2022 (Peer-Reviewed Journal)
- II. **R-CHOP Chemotherapy with a Rituximab Biosimilar (Redditux®) for Patients with de novo Diffuse Large B-cell Lymphoma: First Preliminary Results of a Real-Life Single-Center Experience from Turkey**
Özbalak M. M. , Mastanzade M., Özlük Ö., Tiryaki T. O. , Pınar Özbalak E., Yönel Hindilerden İ., Altay A. Y. , Yegen G., Yenerel M. N. , Nalçacı M., et al.
İstanbul Kanuni Sultan Süleyman Tıp Dergisi , vol.13, no.3, pp.194-198, 2021 (Peer-Reviewed Journal)
- III. **KILLER IMMUNOGLOBULINE LIKE RECEPTOR GENE ANALYSIS IN CHRONIC LYMPHOCYTIC LEUKEMIA AND ITS RELATION WITH AUTOIMMUNITY**
Ozbalak M. M. , Ozunal I. E. , Berk S., ELVERDİ T., SALİHOĞLU A., EŞKAZAN A. E. , Ozbalak E. P. , Cem A. R. , ÖNGÖREN Ş., BAŞLAR Z., et al.
JOURNAL OF ISTANBUL FACULTY OF MEDICINE-ISTANBUL TIP FAKULTESİ DERGISI, vol.84, no.2, pp.227-236, 2021 (ESCI)
- IV. **Initial complete blood count score and predicting disease progression in COVID-19 patients.**
Ozbalak M. M. , Kalayoglu Besisik S., Tor Y. B. , Medetalibeyoglu A., Kose M., Senkal N., Aksoy E., Cagatay A., Erelel M.,

Gul A., et al.

American journal of blood research, vol.11, no.1, pp.77-83, 2021 (ESCI)

- V. **Cytomegalovirus reactivation during adult acute lymphoblastic leukemia maintenance: do we underestimate (un)expected guest of pediatric approach?**
Ozbalak M. M. , Mastanzade M., GÜREL E., BEŞİŞİK S.
AMERICAN JOURNAL OF BLOOD RESEARCH, vol.11, no.1, pp.118-122, 2021 (ESCI)
- VI. **Initial complete blood count score and predicting disease progression in COVID-19 patients**
Ozbalak M. M. , Besisik S., Tor Y. B. , Medetalibeyoglu A., Kose M., Senkal N., Aksoy E., Cagatay A., Erelel M., Gül A., et al.
AMERICAN JOURNAL OF BLOOD RESEARCH, vol.11, no.1, pp.77-83, 2021 (ESCI)
- VII. **Retrospective Analysis of Peripheral T-Cell Lymphoma Patients: Single Center 'Real-Life' Experience**
Beşişik S., Özbalak M. M. , Mastanzade M.
Medical Journal of Bakirkoy, vol.16, no.4, pp.1-7, 2020 (ESCI)
- VIII. **Gıda Kaynaklı İmmünomodülatörler**
Kohansal Koshksaray F., Özbalak M. M. , Balkan İ. İ. , Erten Yurdagül G.
Experimed, vol.10, no.2, pp.97-111, 2020 (Peer-Reviewed Journal)
- IX. **Retrospective Analysis of Peripheral T-Cell Lymphoma Patients: Single Center 'Real-Life' Experience**
Ozbalak M. M. , MASTANZADE M., Ozluk O., TİRYAKİ T. O. , Hindilerden I. Y. , YENEREL M. N. , ALTAY A. Y. , YEGEN G., Dogan I. O. , NALÇACI M., et al.
MEDICAL JOURNAL OF BAKIRKOY, vol.16, no.4, pp.392-398, 2020 (ESCI)
- X. **Bortezomib induced pulmonary toxicity: a case report and review of the literature**
Saglam B., Kalyon H., Ozbalak M. M. , Ornek S., Keske S., Tabak L., Cakar N., Zeren H. N. , Aytekin S., Bolukbasi Y., et al.
AMERICAN JOURNAL OF BLOOD RESEARCH, vol.10, no.6, pp.407-415, 2020 (ESCI)
- XI. **Inflammatory myofibroblastic tumor mimicking a relapse in a patient with Hodgkin's lymphoma: report of an unusual case and review of the literature.**
Özbalak M. M. , Torun E. S. , ÖZDEMİRLİ M., Uçar A. R. , Akpınar T. S. , Taşcıoğlu C., Ferhanoglu B.
Clinical case reports, vol.5, pp.945-949, 2017 (ESCI)
- XII. **Detailed analysis of diffuse large B cell lymphoma patients: a single-center, retrospective study.**
Ozbalak M. M. , Ar M. C. , Tuzuner N., Salihoglu A., Eskazan A. E. , Ongoren Aydin S., Baslar Z., Soysal T., Aydin Y., Barak Dolgun A., et al.
ISRN hematology, vol.2013, pp.908191, 2013 (Refereed Journals of Other Institutions)

Refereed Congress / Symposium Publications in Proceedings

- I. **ASPARAGINASE INDUCED SINUS VEIN THROMBOSIS IN AN ADULT YOUNG ALL PATIENT**
OLUK B., KUBİLAY D. Ö. , ÖZBALAK M. M. , ERDEM S., BEŞİŞİK S.
XIIth Eurasian Hematology-Oncology Congress, İSTANBUL (Hibrit Kongre), Turkey, 10 November 2021, vol.43, pp.77
- II. **WHAT HAVE WE EXPERIENCED WITH COVID-19 IN PATIENTS WITH HEMATOLOGICAL DISORDERS?**
ERDEM S., MASTANZADE M., ÖZBALAK M. M. , KUBİLAY D. Ö. , TİRYAKİ T. O. , OLUK B., YÖNAL HİNDİLERDEN İ., YENEREL M. N. , NALÇACI M., BEŞİŞİK S., et al.
XIIth Eurasian Hematology-Oncology Congress, İSTANBUL (Hibrit Kongre), Turkey, 10 November 2021, vol.43, pp.96
- III. **Yeni tanı DBBHL'de biyobenzer rituksimab (Redditux) içeren R-CHOP rejimi sonuçları: Tek merkez gerçek yaşam deneyimi**
ÖZBALAK M. M. , MASTANZADE M., KUBİLAY D. Ö. , TİRYAKİ T. O. , ERDEM S., Pınar Özbalak E., ELVERDİ T., YÖNAL HİNDİLERDEN İ., YENEREL M. N. , SOYSAL T., et al.
47. Ulusal Hematoloji Kongresi, Antalya, Turkey, 04 November 2021
- IV. **A Case of Congenital Afibrinogenemia with Two Successful Spontaneous Delivery after Recurrent Pregnancy Losses**

Mastanzade M., Özbalak M. M. , Beşışık S.

ISTH 2021 Congress, Pennsylvania, United States Of America, 17 - 21 July 2021, no.5, pp.312

- V. **Increased activity of follicular helper T and cytotoxic T cells in chronic lymphocytic leukemia**
Gelmez M. Y. , Öktelek F. B. , Çınar S. , Özbalak M. M. , Deniz G.
6th European Congress of Immunology (ECI 2021), Belgrade, Serbia, 1 September - 04 October 2021, pp.1
- VI. **Increased activity of follicular helper T and follicular cytotoxic T cells in Chronic Lymphocytic Leukemia**
Gelmez M. Y. , Öktelek F. B. , Çınar S. , Özbalak M. M. , Özlük Ö. , Deniz G., Aktan M.
6th European Congress of Immunology, Belgrade, Serbia, 1 - 04 September 2021, pp.245
- VII. **Dual-Beam optical Manipulation of Red blood cells for the investigation of paroxysmal nocturnal hemoglobinuria**
Parlatan U., Soysal K. B. , Parlattan S., Mastanzade M., Ozbalak M. M. , Yenerel M. N. , Unlu B.
Optical Manipulation and Its Applications, OMA 2021 - Part of Biophotonics Congress: Optics in the Life Sciences 2021, Virtual, Online, United States Of America, 12 - 16 April 2021
- VIII. **A raman tweezer study with single red blood cells for the diagnosis of paroxysmal nocturnal hemoglobinuria**
Parlatan S., Parlattan U., Soysal K. B. , Mastanzade M., Ozbalak M. M. , Yenerel M. N. , Başar G., Unlu B.
Optical Molecular Probes, Imaging and Drug Delivery, OMP 2021 - Part of Biophotonics Congress: Optics in the Life Sciences 2021, Virtual, Online, United States Of America, 12 - 16 April 2021
- IX. **Prognostic value of pre-treatment neutrophil-lymphocyte and platelet-lymphocyte ratio in diffuse large B-cell lymphoma: a single-center experience**
Dağcı G., Mastanzade M., Özbalak M. M. , Kubilay D. Ö. , Tiryaki T. O. , Yönel Hindilerden İ., Yenerel M. N. , Nalçacı M., Beşışık S.
XIth Eurasian Hematology Oncology Congress, İstanbul, Turkey, 21 - 24 October 2020, no.42, pp.48-49
- X. **A retrospective analysis of peripheral T-cell lymphoma patients: single-center 'real-life' experience**
Ozbalak M. M. , Besisik S., Mastanzade M., Ozluk O., Ozmen A., Hindilerden I. Y. , Yenerel M. N. , Nalcaci M.
10th Eurasian Hematology Oncology Congress, İstanbul, Turkey, 8 - 11 October 2019, vol.85
- XI. **A relapsed refractory CD30 positive cutaneous anaplastic large cell lymphoma with large B-cell transformation responding to brentuximab vedotin after multiple lines of treatment**
Erdem S., Ozbalak M. M. , Baykal C., Besisik S.
10th Eurasian Hematology Oncology Congress, İstanbul, Turkey, 8 - 11 October 2019, vol.85
- XII. **Role of [Ga-68]-pentixafor-PET/CT as a novel imaging of cxcr4 expression in multiple myeloma; comparison to [F-18]-FDG-PET/CT**
Tiryaki T. O. , Kuyumcu S., Has-Simsek D., Ozbalak M. M. , Ozluk D., Unal S., Kalayoglu-Besisik S.
10th Eurasian Hematology Oncology Congress, İstanbul, Turkey, 8 - 11 October 2019, vol.85
- XIII. **Role of [68Ga]-pentixafor-PET/CT as a novel imaging of cxcr4 expression in multiple myeloma comparison to [18F]-FDG-PET/CT**
TİRYAKI T. O. , KUYUMCU S., HAS ŞİMŞEK D., ÖZBALAK M. M. , KUBİLAY D. Ö. , ÜNAL S. N. , BEŞİŞİK S.
Xth International Eurasian Hematology-Oncology Congress, İstanbul, Turkey, 8 - 12 October 2019, vol.85
- XIV. **Long-Term Results of Brentuximab Vedotin in Relapsed and Refractory Hodgkin Lymphoma: Multi-Center Real-Life Experience**
Ferhanoglu A. B. , ÖZBALAK M. M. , SALİHOĞLU A., Soysal T., Karadogan I., Paydas S., Ozdemir E., Yildiz B., Karadurmus N., KAYNAR L., et al.
59th Annual Meeting of the American-Society-of-Hematology (ASH), Georgia, United States Of America, 9 - 12 December 2017, vol.130
- XV. **NIVOLUMAB FOR RELAPSED OR REFRACTORY HODGKIN LYMPHOMA: EXPERIENCE IN TURKEY**
Ferhanoglu B., Bekoz H., Karadurmus N., Paydas S., Gulbas Z., Turker A., Toptas T., Tuğlular T. F. , Tekgunduz E., Kaya A. H. , et al.
22nd Congress of the European-Hematology-Association, Madrid, Spain, 22 - 25 June 2017, vol.102, pp.84-85
- XVI. **IS FDG-PET THE MOST SENSITIVE TOOL TO DIAGNOSE BLEOMYCIN INDUCED PNEUMONITIS IN HODGKIN'S LYMPHOMA?**

Ozturk E., Falay O., Bolukbasi Y., Gumu T., Ornek S., ÖZBALAK M. M. , Demirkol O., Ferhanoglu B.

10th International Symposium on Hodgkin Lymphoma, Cologne, Germany, 22 - 25 October 2016, vol.101, pp.43

XVII. **The comparison of up-front autologous peripheral stem cell transplantation in first remission and long-lasting intensive chemotherapy protocols in highly aggressive non-Hodgkin's lymphomas: Results of a retrospective analysis.**

Ozturk M., Ozaydin S., Oyan B., Ozbalak M. M. , Arpacı F., Paydas S., Ataergin S., Ferhanoglu B., Kocak N., Gurkan E., et al.

48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 1 - 06 June 2012, vol.30

Metrics

Publication: 45

Citation (WoS): 110

Citation (Scopus): 107

H-Index (WoS): 6

H-Index (Scopus): 6